Copyright © 2026 Authors retain the copyright of this article. This article is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

@article{205250,
        author = {ACHAL PRAVIN PATMAS and DIPALI HAMDE},
        title = {Colon-Targeted Drug Delivery Systems for Localized Treatment of Inflammatory Bowel Disease},
        journal = {International Journal of Innovative Research in Technology},
        year = {2026},
        volume = {13},
        number = {1},
        pages = {5438-5446},
        issn = {2349-6002},
        url = {https://ijirt.org/article?manuscript=205250},
        abstract = {Inflammatory bowel disease (IBD), encompassing Crohn's Disease and Ulcerative Colitis, is a chronic relapsing inflammatory disorder of the gastrointestinal tract. Conventional systemic therapies often result in suboptimal drug concentrations at the inflamed colonic mucosa and may cause significant adverse effects. Colon-targeted drug delivery systems (CTDDS) have emerged as a promising strategy to enhance therapeutic efficacy while minimizing systemic exposure. These systems exploit the unique physiological characteristics of the colon, including pH variations, transit time, microbial flora, and enzymatic activity, to achieve site-specific drug release. This review discusses the pathophysiology of IBD, the rationale for colon targeting, various colon-targeted delivery approaches, recent advances in nanotechnology-based systems, and current challenges and future perspectives in the field.},
        keywords = {Inflammatory bowel disease, colon-targeted drug delivery, pH-sensitive systems, polysaccharides.},
        month = {June},
        }